Clairity and Myriad Collaborate to Enhance Breast Cancer Risk Assessment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Source: Newsfilter
- Collaborative Innovation: Clairity, Myriad Genetics, and MagView have partnered to launch a new platform aimed at enhancing the identification of high-risk women for breast cancer by integrating genotype and phenotype data, which is expected to significantly improve breast cancer screening processes.
- Technology Integration: The new platform combines Myriad's MyRisk hereditary cancer test with Clairity Breast's AI-powered risk assessment, providing a more comprehensive view of risk that enables clinicians to make earlier, personalized interventions, thereby reducing breast cancer mortality rates.
- Market Impact: MagView's Luminary Risk software is already utilized in over 2,500 healthcare facilities across the U.S., and the integration of this new technology is anticipated to further enhance workflow efficiency and patient experience, driving personalized breast health management.
- Strategic Goals: This collaboration not only addresses a critical gap in breast cancer risk assessment but also aims to reduce administrative burdens, enabling healthcare institutions to achieve more efficient screening and management in cancer care, aligning with the industry's shift towards preventive care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 7.38 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 5.540
Low
4.00
Averages
7.38
High
9.00
Current: 5.540
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Myriad Genetics Unveils Commercialization Roadmap for Precise MRD Assay
- Technological Innovation: Myriad Genetics' Precise MRD assay utilizes ultrasensitive circulating tumor DNA detection to provide critical clinical insights across various cancer types, marking a significant breakthrough in molecular diagnostics.
- Market Launch Plan: The company plans a limited launch of Precise MRD with select community-based clinicians in breast cancer starting March 2026, followed by expansions into colorectal and renal cancers later that year, indicating a phased market entry strategy.
- Clinical Research Findings: Interim clinical studies demonstrate the assay's ability to detect ctDNA down to one part per million, with high baseline sensitivity and strong predictive power for recurrence and treatment response in breast and colorectal cancers, further validating its potential role in precision oncology.
- Academic Recognition: These findings have been presented at leading medical conferences and published in peer-reviewed journals, enhancing the credibility and market acceptance of Precise MRD in real-world applications.
Continue Reading
Myriad Genetics (MYGN) Projects Q4 Revenue of $207M-$209M
- Q4 Revenue Expectations: Myriad Genetics anticipates total revenues for Q4 2025 to be between $207 million and $209 million, reflecting stable growth in the genetic testing market, which may bolster investor confidence.
- Full Year Revenue Outlook: The company projects total revenues for 2025 to range from $822 million to $824 million, indicating sustained market demand and potential for business expansion, which could enhance its competitive position in the industry.
- 2026 Financial Forecast: Myriad Genetics expects revenues for 2026 to be between $860 million and $880 million, with adjusted EBITDA projected between $37 million and $49 million, suggesting an improvement in profitability and financial health in the future.
- Earnings Call Schedule: The company plans to hold an earnings call in February 2026 to release actual financial results for Q4, providing investors with clearer insights into its financial status and future outlook.
Continue Reading